Prognostic value of insulinlike growth factor I and its binding protein in patients with alcohol-induced liver disease

Hepatology

Volumn 23, Issue 5, 1996, Pages 1073-1078

  Møller, Søren ^a,b   Becker, Ulrik ^a   Juul, Anders ^a   Skakkebæk, Niels E ^a   Christensen, Erik ^a   Keiding, S ^c   Badsberg, J H ^a   Bentsen, K D ^d   Bonnevie, O ^e   Caballeria, J ^f   Eriksen, J ^e   Hardt, F ^b   Keiding, N ^a   Morgan, M ^g   Poulsen, H ^b   Ranek, L ^h   Rodes J ^f   Schou, G ^f   Walker, R ⁱ   Tygstrup, N ^f  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e FREDERIKSBERG HOSPITAL   (Denmark)

^f HOSPITAL CLÍNIC   (Spain)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h Rigshospitalet   (Denmark)

ⁱ WALTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MALOTILATE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ALCOHOL LIVER DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

EID: 15844393277     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v23.pm0008621136     Document Type: Article

References (23)

1. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor 1 in healthy adults. N Engl J Med 1987;317:137-140.
2. Hartmann H, Schmitz F, Christ B, Jungermann K, Creutzfeldt W. Metabolic actions of insulin-like growth factor-1 in cultured hepatocytes from adult rats. HEPATOLOGY 1990;12:1139-1143.
3. Cohick WS, Clemmons DR. The insulin-like growth factors. Annu Rev Physiol 1993;55:131-153.
4. Langford KS, Miell JP. Review: the insulin-like growth factor-I/binding protein axis: physiology, pathophysiology and therapeutic manipulation. Eur J Clin Invest 1993;23:503-516.
5. Blum WF, Ranke MB. Insulin-like growth factor binding proteins (IGFBPs) with special reference to IGFBP-3. Acta Pædiatr Scand 1990;367(suppl):55-62.
6. Baxter RC. Circulating binding proteins for the insulin-like growth factors. Trends Endocrinol Metab 1993;4:91-96.
7. Møller S, Becker U. Insulin-like growth factor-I and growth hormone in chronic liver disease. Dig Dis Sci 1992;10:239-248.
8. Sheppard MS, Minuk GY, Bhaumick B, Bala RM. Insulin-like growth factors (IGF) in liver disease: differential changes of IGFI and IGF-II. Clin Invest Med 1987;10:49-53.
9. Wu JC, Daughaday WH, Lee SD, Hsiao TS, Chou CK, Lin HD, Tsai YT, et al. Radioimmunoassay of serum IGF-1 and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. J Lab Clin Med 1988;112:589-594.
10. Kratzsch J, Blum WF, Schenker E, Keller E. Serum levels of IGF-I, IGF-binding proteins (IGFBP) 1, 2 and 3 and GHBP in liver cirrhosis. Presented at the 31st Annual Meeting of ESPE. Horm Res 1992;37(suppl 4):55.
11. Møller S, Juul A, Becker U, Flyvbjerg A, Skakkebæk NE, Henriksen JH. Concentrations, release, and disposal of insulin-like growth factor (IGF)-binding proteins (IGFBP), IGF-I, and growth hormone in different vascular beds in patients with cirrhosis. J Clin Endocrinol Metab 1995;80:1148-1157.
12. Donaghy A, Ross R, Gimson A, Cwyfan Hughes S, Holly J, Williams R. Growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins 1 and 3 in chronic liver disease. HEPATOLOGY 1995;21:680-688.
13. Caufriez A, Reding P, Urbain D, Golstein J, Copinschi G. Insulinlike growth factor I: a good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis. J Endocrinol Invest 1991; 14:317-321.
14. Møller S, Grønbæk M, Main K, Becker U, Skakkebæk NE. Urinary growth hormone (U-GH) excretion and serum insulin-like growth factor-I (IGF-I) in patients with alcoholic cirrhosis. J Hepatol 1993;17:315-320.
15. Kratzsch J, Blum WF, Schenker E, Keller E, Jahreis G, Haustein B, Ventz M, et al. Measurement of insulin-like growth factor-I (IGF-I) in normal adults, patients with liver cirrhosis and acromegaly: experience with a new competitive enzyme immunoassay. Exp Clin Endocrinol 1993;101:144-149.
16. Christensen E, Schlichting P, Fauerholdt L, Juhl E, Poulsen H, Tygstrup N, The Copenhagen Study Group for Liver Diseases. Changes of laboratory variables with time in cirrhosis: prognostic and therapeutic significance. HEPATOLOGY 1985;5:843-853.
17. Christensen E, Schlichting P, Kragh-Andersen P, Fauerholdt L, Schou G, Vestergaard Pedersen B, Juhl E, et al. Updating prognosis and therapeutic effect evaluation in cirrhosis with Cox's multiple regression model for time-dependent variables. Scand J Gastroenterol 1986;21:163-174.
18. Keiding S, Badsberg JH, Becker U, Bentsen KD, Bonnevie O, Caballeria J, Eriksen J, et al. The prognosis of patients with alcoholic liver disease: an international randomized, placebocontrolled trial on the effect of malotilate on survival. J Hepatol 1994;20:454-460.
19. Bang P, Eriksson U, Sara V, Wivall IL, Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol 1991;124:620-629.
20. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jørgensen K, Müller J, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents and adults; relation to age, sex, stage of puberty, testicular size and body mass index. J Clin Endocrinol Metab 1994;78:744-752.
21. Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR. A specific radioimmunoassay for growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 1990;70:1292-1298.
22. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebæk NE. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, -2, and -3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol 1994;41:85-93.
23. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:l-39.